For generations, cancer treatment has asked patients to bear the uncertainty of trial and error — enduring drugs that may not work, or that work in ways no one predicted. Researchers at the University of Kentucky have developed a microarray chip that tests a liver cancer patient's own tumor tissue against multiple targeted drugs before any treatment begins, offering oncologists a map of what will work, what will fail, and what hidden risks may lie ahead. The platform has already revealed that certain ABL-inhibiting drugs behave differently in male and female patients — a finding with real cons